Our research is aimed at finding more effective therapeutics for the most common form of pediatric brain tumor: medulloblastoma. Due to the poor survival numbers that children with relapsed medulloblastoma have, we intend to uncover the signaling mechanisms allowing these tumors to re-grow after treatment. By using bioinformatic analyses, followed by series of ex vivo and in vivo studies, we hope to find treatments ensuring a long-term and stable tumor remission. Moreover, the targeted nature of our treatment approaches should show fewer co-morbidities in pediatric patients than current adjuvant chemotherapeutics targeting any cell in proliferation.